Boston Trust Walden’s Genesee & Wyoming Inc. GWR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-135,710
Closed -$9.21M 377
2017
Q1
$9.21M Sell
135,710
-8,949
-6% -$647K 0.14% 183
2016
Q4
$10M Sell
144,659
-2,987
-2% -$213K 0.16% 178
2016
Q3
$10.2M Buy
147,646
+1,560
+1% +$102K 0.17% 171
2016
Q2
$8.61M Sell
146,086
-1,179
-0.8% -$72.2K 0.15% 184
2016
Q1
$9.23M Sell
147,265
-38,264
-21% -$2.1M 0.16% 181
2015
Q4
$9.96M Sell
185,529
-46,751
-20% -$2.96M 0.18% 173
2015
Q3
$13.7M Buy
232,280
+181,368
+356% +$12.5M 0.23% 166
2015
Q2
$3.88M Sell
50,912
-1,205
-2% -$106K 0.06% 232
2015
Q1
$5.03M Sell
52,117
-2,441
-4% -$228K 0.07% 214
2014
Q4
$4.91M Sell
54,558
-577
-1% -$53.3K 0.07% 213
2014
Q3
$5.25M Sell
55,135
-857
-2% -$85.1K 0.08% 206
2014
Q2
$5.88M Sell
55,992
-222
-0.4% -$21.8K 0.09% 195
2014
Q1
$5.47M Sell
56,214
-745
-1% -$70.6K 0.08% 197
2013
Q4
$5.47M Sell
56,959
-44
-0.1% -$4.24K 0.08% 196
2013
Q3
$5.3M Sell
57,003
-56,334
-50% -$5.09M 0.08% 196
2013
Q2
$9.62M Buy
+113,337
New +$9.9M 0.16% 173

Other funds holding GWR

Boston Trust Walden's GWR Position: Q2 2017 in Review

Boston Trust Walden sold out of Genesee & Wyoming Inc. (GWR) in Q2 2017, closing a stake of 135,710 shares — an estimated $9.21M sold.

Boston Trust Walden first reported a position in GWR in Q2 2013 and held it in 16 quarters. The position peaked at $13.7M in Q3 2015. 269 funds tracked by Wall St. Rank hold GWR as of Q2 2017.

  • Boston Trust Walden reported no remaining Genesee & Wyoming Inc. position as of Q2 2017 after selling out during the quarter.
  • Boston Trust Walden sold 135,710 Genesee & Wyoming Inc. shares in Q2 2017, an estimated $9.21M.
  • Boston Trust Walden first reported a position in Genesee & Wyoming Inc. in Q2 2013 and held it in 16 quarters.
  • Boston Trust Walden's Genesee & Wyoming Inc. position peaked at $13.7M in Q3 2015.
  • 269 funds tracked by Wall St. Rank held Genesee & Wyoming Inc. as of Q2 2017.

Based on Boston Trust Walden's 13F filing for Q2 2017, filed 19 Jul 2017.